Recent News

• 06.09.2026 - 8-K - Current report
• 06.03.2026 - 3 - Initial statement of beneficial ownership of securities
• 06.03.2026 - 4 - Statement of changes in beneficial ownership of securities
• 06.03.2026 - 8-K - Current report
• 06.03.2026 - Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer
• 06.01.2026 - CORRESP - Correspondence
• 06.01.2026 - UPLOAD - SEC-generated letter
• 05.27.2026 - DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.27.2026 - DEF 14A - Definitive proxy statements
• 05.26.2026 - 8-K - Current report

Recent Filings

• 06.03.2026 - 3 Initial statement of beneficial ownership of securities
• 06.03.2026 - EX-99.1 EX-99.1
• 06.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.03.2026 - 8-K Current report
• 05.27.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.27.2026 - DEF 14A Other definitive proxy statements
• 05.26.2026 - EX-99.1 EX-99.1
• 05.26.2026 - 8-K Current report